Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Gross Margin (2017 - 2026)

Lexaria Bioscience's Gross Margin history spans 10 years, with the latest figure at 100.0% for Q1 2026.

  • Quarterly results put Gross Margin at 100.0% for Q1 2026, changed 0.0% from a year ago — trailing twelve months through Feb 2026 was 100.0% (up 52.0% YoY), and the annual figure for FY2025 was 99.61%, up 65.0%.
  • Gross Margin for Q1 2026 was 100.0% at Lexaria Bioscience, roughly flat from 100.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 3796.9% in Q3 2022 to a low of 79.16% in Q1 2022.
  • The 5-year median for Gross Margin is 100.0% (2023), against an average of 355.73%.
  • The sharpest move saw Gross Margin skyrocketed 379673bps in 2022, then plummeted -369690bps in 2023.
  • Year by year, Gross Margin stood at 83.84% in 2022, then increased by 15bps to 96.81% in 2023, then rose by 2bps to 98.52% in 2024, then increased by 2bps to 100.0% in 2025, then changed by 0bps to 100.0% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods came in at 100.0%, 100.0%, and 100.0% for Q1 2026, Q3 2025, and Q2 2025 respectively.